Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Midcaps and smallcaps in the limelight
Thu, 14 Oct 01:30 pm

Indian indices continue to trade flat as investors consolidated their positions over the previous two hours of trade. Stocks from the realty and metal space are trading firm while stocks from the consumer goods and power space are trading weak.

The BSE-Sensex is down by 14 points while NSE-Nifty is trading 3 points above the dotted line. BSE-Midcap is up by 0.5% while BSE-Smallcap index is trading 0.4% above yesterday's closing. The rupee is trading at 44.17 to the US dollar.

FMCG stocks are trading mixed with Godrej Consumer and Camlin trading firm while P&G and Gillette are trading weak. As per a press release, the board of Godrej Consumer Products Limited (GCPL) has approved the merger of Godrej Household Products Ltd. with itself. This merger has been effective since April 1, 2010, subsequent to GCPL's acquisition of Sara Lee's 51% stake in Godrej Sara Lee. This merger consolidates GCPL's position in the Indian FMCG space making it the largest homegrown household and personal care company in India and second largest household insecticides company in Asia (ex Japan). This merger is expected to provide GCPL significant strategic and operational benefits as well as scale of operations.

Healthcare stocks are currently trading firm led by Aurobindo Pharma, Biocon and Piramal Healthcare. The stock of Cadila Healthcare is trading higher on the back of news of it launching ‘Pramipexole' tablets in the US. This medicine will be available in multiple strengthens in the market. This drug is used to treat Parkinson's disease. According to estimates made by the NDC Health, the annual sales of this drug in US market is estimated at US$ 632 m (approximately Rs 28 bn) in 2010. This drug is the generic version of ‘Mirapax' manufactured by a German pharmaceutical company named Boehringer Ingelheim. It has further been reported that Cadila has about 56 approvals and has filed for 113 Abbreviated New Drug Applications (ANDA) before the US health regulator. This is a definite positive for the company as it would help it boost revenues from the US market.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Midcaps and smallcaps in the limelight". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.